UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.

Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron Hj Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J Swen

Pharmacogenomics 2023 Jun

filter terms:

Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.

Citation

Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron Hj Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J Swen. UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety. Pharmacogenomics. 2023 Jun;24(8):435-439